| Abbott Laboratories Patent applications |
| Patent application number | Title | Published |
|---|
| 20120034117 | METHODS AND SYSTEMS FOR FORMING A TUBE FOR USE WITH A PUMP DELIVERY SYSTEM - In a method and system for forming tubing to achieve at least one predetermined performance characteristic relating to the flow of a flowable material therethrough, a relationship is determined between at least one material characteristic of the tubing material, at least one operating parameter of the tube forming machine, and the at least one predetermined performance characteristic of the tubing. Based on this relationship, at least one operating parameter for operation of the tube forming machine to achieve the at least one predetermined performance characteristic is determined. The at least one operating parameter is input into the tube forming machine and the machine is operated to achieve the at least one predetermined performance characteristic. | 02-09-2012 |
| 20120028925 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES - Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein. | 02-02-2012 |
| 20120028908 | Methods of Manufacturing Crystalline Forms of Rapamycin Analogs - A process for preparing a crystalline rapamycin analog includes: combining the rapamycin analog with an organic medium to form a mixture; incubating the mixture until the rapamycin analog crystallizes; and recovering the crystalline rapamycin analog. The organic medium can be a solvent, and the process can include causing the rapamycin analog to dissolve into the solvent, and incubating the solvent until the rapamycin analog crystallizes. The following can also be performed: forming a slurry of crystalline rapamycin analog; stirring the rapamycin analog mixture until the rapamycin analog crystallizes; saturating the rapamycin analog solution; forming a supersaturated rapamycin analog solution; combining an antisolvent with the rapamycin analog and the solvent to form a biphasic mixture, and incubating the biphasic mixture to cause a liquid-liquid phase split. | 02-02-2012 |
| 20120022253 | INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS - Compounds having the formula | 01-26-2012 |
| 20120022252 | PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS - The disclosure is directed to: (a) phosphacycle ligands; (b) methods of using such phosphacycle ligands in bond forming reactions; and (c) methods of preparing phosphacycle ligands. | 01-26-2012 |
| 20120022103 | ANTAGONISTS OF THE TRPV1 RECEPTOR AND USES THEREOF - The present application is directed to compounds that are TRPV1 antagonists and have formula (I) | 01-26-2012 |
| 20120022089 | Solid Pharmaceutical Dosage Form - A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50° C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10. | 01-26-2012 |
| 20120020972 | ANTIBODIES RELATING TO PIVKA-II AND USES THEREOF - The present disclosure relates to antibodies and immunoassay methods for use in the diagnosis, treatment and prevention of hepatocellular carcinoma (HCC), liver cancer and related conditions. | 01-26-2012 |
| 20120015963 | NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS - The present disclosure is directed to novel compounds of Formula (I) | 01-19-2012 |
| 20120015929 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS - Disclosed herein are compounds of formula (I) | 01-19-2012 |
| 20120014913 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS - This disclosure is directed to: (a) processes for preparing a compound and salts thereof that, inter alia, are useful for inhibiting hepatitis C virus (HCV); (b) intermediates useful for the preparation of the compound and salts; (c) pharmaceutical compositions comprising the compound or salts; and (d) methods of use of such compositions. | 01-19-2012 |
| 20120009196 | MONOCLONAL ANTIBODIES AGAINST HEPATITIS C VIRUS CORE PROTEIN - The present disclosure relates to anti-HCV core protein monoclonal antibodies, methods of making them, and their uses in the prevention, diagnosis, and/or treatment of disease including HCV infections. | 01-12-2012 |
| 20120002501 | MIXING SYSTEM FOR MIXING A POWDERED BEVERAGE WITH A LIQUID - In a mixing system for mixing together a powdered beverage and a liquid in-situ to form a ready-to-drink beverage, a receptacle has an interior space defining a mixing chamber for receiving powdered beverage and liquid therein to be mixed. An agitator is removably disposed in the mixing chamber, the agitator being operable to mix the powdered beverage and liquid within the mixing chamber, said agitator being removable from the receptacle. A retention member is configured to inhibit the agitator against falling out of the receptacle upon substantially inverting the receptacle. A drive system is provided for operating the agitator, with the agitator and drive system being configured for operative coupling therebetween. The mixing system may include a support for supporting the receptacle in an upright orientation. The receptacle may be removable from the support. The agitator may include an anti-vortex member to inhibit formation of a vortex. | 01-05-2012 |
| 20120000934 | DISPENSING APPLIANCE FOR DISPENSING A BEVERAGE FROM A POWDERED BEVERAGE CONTAINER - In a dispensing appliance for dispensing a beverage from a powdered beverage container, a cartridge includes a container containing powdered beverage, and a dispenser on the container operable to dispense powdered beverage from the container. The appliance includes a mount for removably supporting the cartridge on the dispensing appliance, and a drive system configured for operative connection with the dispenser upon loading of the cartridge into the mount. The drive system is operable to operate the dispenser to release powdered beverage from the container. The beverage may be dispensed from the appliance in its powder form, or mixed with a liquid and dispensed generally in a liquid form. In a method of refilling a dispensing appliance, an empty cartridge of powdered beverage is replaced with a new, substantially full cartridge of powdered beverage with the cartridge dispenser operatively connected to the drive system of the appliance. | 01-05-2012 |
| 20120000929 | PACKAGING FOR POWDERED BEVERAGE AND DISPENSER THEREFOR - Packaging for a powdered beverage includes a container of powdered beverage, and a dispenser secured to the container. The dispenser includes an outer dispensing member having an exit opening, and an inner dispensing member in opposed relationship with the outer dispensing member and in part defining an interior space of the container. The inner dispensing member has at least one dispensing opening. At least one of the outer dispensing member and the inner dispensing member is moveable relative to the other one of the outer dispensing member and the inner dispensing member between a blocked position and a dispensing position of the dispenser in which the at least one opening of the inner dispensing member is at least in part aligned with the exit opening of the outer member to permit powdered beverage to be dispensed from the packaging. | 01-05-2012 |
| 20120000791 | METHOD OF DESCALING METALLIC DEVICES - Methods are provided for descaling metallic component devices such as stents. The devices or components are cleaned under ultrasound in a cleaning solution of ammonium hydrogen fluoride at a temperature within a range of about 60° to 80° C., then rinsed at that temperature with an aqueous rinse containing a nonionic surfactant and rinsed again with purified water. | 01-05-2012 |
| 20110312010 | COMPARISON OF PROTEIN SAMPLES - Methods of qualitatively and/or quantitatively detecting the presence of mutations, modifications or impurities in a protein sample are provided. The methods utilize isotopically labeled variants of amino acids incorporated into proteins prior to protein digest to enable comparisons of two protein samples in bottom-up liquid chromatography. | 12-22-2011 |
| 20110311572 | NUCLEOTIDE AND AMINO ACID SEQUENCES ENCODING AN EXPORTED PROTEIN 1 DERIVED FROM PLASMODIUM VIVAX AND USES THEREOF - The present invention is directed to novel polynucleotides and polypeptides directed to EXP1 of | 12-22-2011 |
| 20110311474 | Novel Tricyclic Compounds - The invention provides compounds of Formula (I) and Formula (II) | 12-22-2011 |
| 20110306632 | Solid Dispersions Containing Kinase Inhibitors - A solid dispersion comprises, in essentially non-crystalline form, a kinase inhibitory compound, e.g., N-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl}phenyl)-N′-(3-fluorophenyl)urea, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a cancer. | 12-15-2011 |
| 20110306616 | Novel Compounds as Cannabinoid Receptor Ligands - Disclosed herein are cannabinoid receptor ligands of formula (I) | 12-15-2011 |
| 20110305799 | SUBSTANTIALLY CLEAR NUTRITIONAL LIQUIDS COMPRISING CALCIUM HMB AND SOLUBLE PROTEIN - Disclosed are substantially clear nutritional liquids comprising protein and calcium HMB wherein soluble protein represents from about 65% to 100% by weight of total protein. The liquids have a pH of from about 2.8 to about 4.6 and may be manufactured as a hot fill product. The substantially clear nutritional liquids may also have a weight ratio of calcium HMB to soluble calcium of from 4.5:1 to 7.3:1. In some embodiments, the substantially clear nutritional liquids are substantially free of fat, and may optionally include isomaltulose and/or beta alanine. | 12-15-2011 |
| 20110300540 | METHODS AND PROBE COMBINATIONS FOR DETECTING MELANOMA - The present invention is based on the discovery of methods and combinations of probes to chromosomal regions that are gained or lost or imbalanced in melanoma that provide highly specific and sensitive assays for the detection of melanoma cells. | 12-08-2011 |
| 20110297306 | METHOD FOR MOLDING AN OBJECT CONTAINING A RADIO FREQUENCY IDENTIFICATION TAG - A method for applying a radio frequency identification tag to an object, e.g., a container, by means of an insert molding process or in-mold decorating process. Such a method can be utilized to simplify the manufacturing processes for applying a radio frequency identification tag to an object, e.g., a container. The molding process can be a conventional molding process, such as, for example, injection molding, blow molding, compression molding, transfer molding, and rotational molding. However, the conventional molding process is modified by inserting a radio frequency identification tag into the cavity of the mold prior to forming the molded article. The modified molding process results in a molded article having a radio frequency identification tag encapsulated by the polymeric material of the molded article. | 12-08-2011 |
| 20110294994 | Gentamicin Separation Method - The invention provides more effective methods of separating the components of gentamicin using a UV active protecting group suitable for use with HPLC. | 12-01-2011 |
| 20110294854 | SUBSTITUTED OCTAHYDROCYCLOPENTA[c]PYRROLES AS CALCIUM CHANNEL MODULATORS - The present application relates to calcium channel inhibitors containing compounds of formula (I) | 12-01-2011 |
| 20110294811 | ABT-263 CRYSTALLINE FORMS - ABT-263 free base and crystalline forms thereof are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer. | 12-01-2011 |
| 20110294198 | DISPOSABLE CHAMBER FOR ANALYZING BIOLOGIC FLUIDS - An apparatus for analyzing biologic fluid is provided that includes first and second planar members, and at least three separators. At least one of the first planar member and second planar member is transparent. The separators are disposed between the planar members, and each individually has a height. The separators collectively having a mean height, and separate the planar members to form a chamber having a height extending between the planar members. At least one of the first planar member, second planar member, or separators is sufficiently deformable when the first planar member and second planar member are drawn toward each other by capillary force from a biologic fluid quiescently residing within the chamber to cause the mean chamber height to be substantially equal to the mean height of the separators. | 12-01-2011 |
| 20110294140 | Lysis Reagent For Use With Capture-In-Solution Immunoassay - The invention provides a lysis reagent and method for preparing a test sample for use in an assay, wherein the method yields a homogeneous lysis mixture suitable for use in automated pipetting systems without the need for a centrifugation step. The lysis reagent includes a glycol and non-specific animal immunoglobulins. Other aspects of the invention include related immunoassays and test kits. | 12-01-2011 |
| 20110293744 | BENZOXAZOLE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE - Inhibitors of poly(ADP-ribose)polymerase having a structure of Formula (I), ways to make them and methods of treating patients using them are disclosed. | 12-01-2011 |
| 20110288129 | AMIDE DERIVATIVES AS TRPV1 ANTAGONISTS - The present invention relates to compounds of formula (I), or pharmaceutically acceptable salts, prodrugs, salts of prodrugs, or combinations thereof, | 11-24-2011 |
| 20110288069 | Benzodiazepine and Pyridodiazepine Derivatives - The present application relates to benzodiazepine and pyridodiazepine derivatives of formula (I) | 11-24-2011 |
| 20110287555 | REUSABLE SHEATHS FOR SEPARATING MAGNETIC PARTICLES - An assembly that utilizes reusable sheaths for covering magnetic rods for collecting particles in an inverse magnetic particle process. The magnetic rod is removed from the reusable sheath to release particles at the same or a different location. The reusable sheaths can be assembled in a cylindrical plate, which can be rotated to position a clean sheath for each step of the inverse magnetic particle process. When not being used for particle separation, the sheaths can be washed of potentially contaminating solution in wash receptacles. | 11-24-2011 |
| 20110284498 | METHOD OF REDUCING RIGIDITY OF ANGIOPLASTY BALLOON SECTIONS - A dilatation balloon is fabricated according to a process that forms cavities and indentations in the balloon and/or catheter sections. A length of tubing is axially elongated and radially expanded in a form to provide the requisite biaxial orientation and strength. Then, an excimer laser or another type of laser or mechanical material removal tool is used to remove the polymeric material, virtually without thermal effects. Cavities in the sleeve sections of the balloon are defined and if desired, indentations in the cone sections are defined. Material removal, particularly near the balloon sleeves enables a thinner, more flexible bonding area between the catheter shaft and the balloon. Further, the indentations along the cone sections enables tighter wrapping of the balloon for a reduced delivery profile. Rigidity near the sleeves is reduced for better maneuverability of the catheter in tortuous passageways. | 11-24-2011 |
| 20110281900 | Crystalline Pharmaceutical - New crystalline forms of lopinavir are disclosed. | 11-17-2011 |
| 20110281870 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS - The present application relates to calcium channel inhibitors containing compounds of formula (I) | 11-17-2011 |
| 20110281868 | INDAZOLE INHIBITORS OF KINASE - The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, | 11-17-2011 |
| 20110281842 | PYRROLOPYRIDINE AND PYRROLOPYRIMIDINE INHIBITORS OF KINASES - The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, | 11-17-2011 |
| 20110281258 | Human Immunodeficiency Virus And Uses Thereof - The present invention relates to Human Immunodeficiency Virus-1 (HIV-1) Group P of the strain designated 06CMU14788 and fragments thereof, primers which are derived from HIV-1 Group P, immunogenic regions thereof, immunoassays and nucleic acid based assays for the detection of Human Immunodeficiency Virus (HIV) that employ said HIV-1 Group P or fragments thereof and therapeutic compositions containing said HIV-1 Group P or fragments thereof. | 11-17-2011 |
| 20110280800 | IL-1 BINDING PROTEINS - Proteins that bind IL-1α and IL-1β are described along with their use in compositions and methods for treating, preventing, and diagnosing IL-1-related disorders and for detecting IL-1α and IL-1β in cells, tissues, samples, and compositions. | 11-17-2011 |
| 20110275630 | ISOINDOLINONE KINASE INHIBITORS - Compounds having the formula: | 11-10-2011 |
| 20110275064 | METHOD FOR HEMATOLOGY ANALYSIS - A method whereby one or more fluorescent dyes are used to bind and stain nucleic acids in certain blood cells, such as, for example, white blood cells, nucleated red blood cells, and reticulocytes, and to induce fluorescent emissions upon excitation of photons from a given source of light, such as, for example, a laser, at an appropriate wavelength. More particularly, this invention provides a method whereby a fluorescent trigger is used in a data collection step for collecting events that emit strong fluorescence, in order to separate white blood cells and nucleated red blood cells from red blood cells and platelets without the need for using a lysing agent. | 11-10-2011 |
| 20110273547 | STAGGERED CONTACT IMAGE SENSOR IMAGING SYSTEM - A method and an apparatus for imaging a biologic sample is provided. The apparatus includes at least one light source, at least one lens array, at least one image detector, a positioning system, and an image processor. The lens array has a plurality of lengthwise extending rows, which rows are successively arranged in a widthwise direction. Each row has a plurality of micro lenses, with each micro lens having a resolution field. Each micro lens is adapted to receive light from the illuminated region of the sample and to produce a beam of light. Each row includes a first micro lens and the first micro lens in each successive row is offset from the first micro lens in the previous row by a predetermined amount extending in the lengthwise direction. The offset between successive rows aligns the resolution fields of the micro lenses to collectively create a continuous resolution field across the length of the lens array. The positioning system moves the lens array and image detector relative to the sample, or vice versa, or both. The image processor produces an image signal indicative of the illuminated region of the sample produced from data signals from the image detector. | 11-10-2011 |
| 20110269708 | P2X7 ANTAGONISTS TO TREAT AFFECTIVE DISORDERS - The present invention provides methods to treat mood disorders and anxiety disorders using antagonists of the P2X | 11-03-2011 |
| 20110263827 | Dual Variable Domain Immunnoglobulins and Uses Thereof - The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease. | 10-27-2011 |
| 20110263436 | RECOMBINANT ANTIBODIES AGAINST HEPATITIS C VIRUS AND METHODS OF OBTAINING AND USING SAME - Recombinant antibodies, including chimeric antibodies, specific for hepatitis C (HCV) antigenic proteins are provided. The recombinant antibodies specifically bind to diagnostically relevant regions of HCV proteins and are thus suitable for use, for example, as diagnostic reagents for the detection of HCV, and/or as standardization reagents or positive control reagents in assays for the detection of HCV. The recombinant antibodies can also be used in the treatment or prevention of a HCV infection. | 10-27-2011 |
| 20110262924 | MOLECULAR ASSAY FOR DIAGNOSIS OF HIV TROPISM - The invention is directed to compositions, methods and kits for HIV subtypes in a test sample, wherein target sequence are amplified. The amplified target sequences are then analyzed by any number of mass spectrometric techniques, which data are queried against a database of base composition signatures of HIV subtypes. | 10-27-2011 |
| 20110259847 | BOTTLE PACKAGING FOR FLOWABLE PRODUCT - A bottle packaging includes a groove on the neck of a bottle with the groove spaced longitudinally from a shoulder of the bottle a distance greater than or equal to a width of the groove, and upper and lower portions of the neck may have outer transverse cross-sectional dimensions that are substantially equal to one another. An upper circumferential sidewall of the groove may be chamfered, while a lower circumferential sidewall may be concave. The bottle may be combined with an adapter such that when the adapter is releasably connected to the bottle, a lowermost rim of the adapter is spaced longitudinally from an upper reach of the groove. The adapter may include a detent on an inner surface thereof adapted to removably seat in the groove to releasably connect the adapter to the bottle. A closure member may include at least one of a detent and a sealing member removably seated in the groove. | 10-27-2011 |
| 20110257675 | VENA CAVA FLITER HAVING HOURGLASS SHAPE - The present invention is a luminal filter including: a plurality of filter elements interconnected so as to form a filter body shaped in a free recovery form and having a plurality of apertures disposed between and defined by the interconnected filter elements. The apertures are dimensioned so as to inhibit a thrombus of a selected size from passing through the apertures and being dimensioned so as to allow blood components smaller than the selected size to pass through the apertures. The filter body includes a first funnel and second funnel coupled at least indirectly coupled together at their small ends. | 10-20-2011 |
| 20110257189 | PYRROLOPYRAZINONE INHIBITORS OF KINASES - The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, | 10-20-2011 |
| 20110257187 | PHTHALAZIN-(2H)-ONE INHIBITORS OF KINASES - The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, | 10-20-2011 |
| 20110257152 | PYRROLOPYRIDINE INHIBITORS OF KINASES - The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, | 10-20-2011 |
| 20110256260 | METHODS AND COMPOSITIONS FOR SYNTHESIS OF LONG CHAIN POLYUNSATURATD FATTY ACIDS - The present invention relates to fatty acid desaturases able to catalyze the conversion of oleic acid linoleic acid, linoleic acid to γ-linolenic acid, or of alpha-linolenic acid to stearidonic acid. Nucleic acid sequences encoding desaturases, nucleic acid sequences which hybridize thereto, DNA constructs comprising a desaturase gene, and recombinant host microorganism or animal expressing increased levels of a desaturase are described. Methods for desaturating a fatty acid and for producing a desaturated fatty acid by expressing increased levels of a desaturase are disclosed. Fatty acids, and oils containing them, which have been desaturated by a desaturase produced by recombinant host microorganisms or animals are provided. Pharmaceutical compositions, infant formulas or dietary supplements containing fatty acids which have been desaturated by a desaturase produced by a recombinant host microorganism or animal also are described. | 10-20-2011 |
| 20110256138 | AMYLOID-BETA BINDING PROTEINS - The present invention relates to amyloid-beta (Aβ) binding proteins. Antibodies of the invention have high affinity to Aβ(20-42) globulomer or any Aβ form that comprises the globulomer epitope. Method of making and method of using the antibodies of the invention are also provided. | 10-20-2011 |
| 20110250340 | SHELF STABLE NUTRITIONAL LIQUIDS COMPRISING BETA ALANINE - Disclosed are shelf-stable nutritional liquids comprising beta alanine, protein, and a carbohydrate system, wherein the shelf-stable nutritional liquid includes a molar ratio of the DE of the carbohydrate system to the lysine amino nitrogen of the protein of less than about 1.0 and or a molar ratio of the DE of the carbohydrate system to the beta alanine of less than about 3.0. The nutritional liquids are surprisingly stable over extended periods of time and exhibit minimal reduction in the concentration of beta alanine over shelf life. | 10-13-2011 |
| 20110238089 | TISSUE CLOSURE SYSTEM AND METHODS OF USE - A system for closing an opening in tissue includes a closure element having a coiled body and a plurality of tissue engaging portions disposed about at least a portion of the body, the body being formed of a resilient material. The system also includes a clip applier apparatus that is configured to deploy the closure element into the tissue. | 09-29-2011 |
| 20110237793 | PROCESS FOR PREPARING ANTIVIRAL COMPOUND - This invention is directed to: (a) processes for preparing a compound and salts thereof that, inter alia, are useful for inhibiting hepatitis C virus (HCV); (b) intermediates useful for the preparation of the compound and salts; (c) pharmaceutical compositions comprising the compound or salts; and (d) methods of use of such compositions. | 09-29-2011 |
| 20110237675 | PHARMACEUTICAL FORMULATIONS - The present invention provides a modified release formulation comprising an active agent in a hydrophilic polymer matrix wherein the active agent is a salt of fenofibric acid wherein the release rate of the formulation in an in vitro dissolution is substantially independent of the ionic strength of the dissolution media. | 09-29-2011 |
| 20110237553 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES - Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein. | 09-29-2011 |
| 20110230946 | EASY MARKER PLACEMENT BALLOON MOLD - A catheter balloon is formed from a mold process in which raised dimples or shallow divots are formed on the outer surface using indentations or raised beads on the mold surface. The dimples or divots are located at the transition between the body portion of the catheter balloon and the neck or taper section. The presence of the dimples or divots serves the dual purpose of identifying the transition between the two regions for placing a visual marker on the balloon to be used in positioning the balloon, and also to assist in the retention of a vascular stent on the balloon. | 09-22-2011 |
| 20110230459 | LACTAM ACETAMIDES AS CALCIUM CHANNEL BLOCKERS - The present application relates to calcium channel inhibitors containing compounds of formula (I) | 09-22-2011 |
| 20110229921 | METHODS OF ASSAYING URINARY NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN (uNGAL) IN THE PROGNOSIS OF CADAVERIC KIDNEY TRANSPLANT FUNCTION IN A PATIENT, INCLUDING A PATIENT DIAGNOSED WITH DELAYED GRAFT FUNCTION (DGF), A METHOD OF ASSAYING uNGAL IN THE ASSESSMENT OF RISK OF DGF IN A PATIENT DIAGNOSED WITH EARLY GRAFT FUNCTION (EGF), AND RELATED KITS - A method of prognosticating cadaveric kidney transplant function in a patient; a method of prognosticating cadaveric kidney transplant function in a patient diagnosed with DGF; a method of assessing risk of DGF in a patient, who has been diagnosed with EGF; and a kit comprising at least one component for assaying urine from a patient for NGAL and instructions for assaying the urine for NGAL and assessing cadaveric kidney transplant function or risk of DGF in the patient. | 09-22-2011 |
| 20110228271 | METHOD AND APPARATUS FOR RAPIDLY COUNTING AND IDENTIFYING BIOLOGICAL PARTICLES IN A FLOW STREAM - A method for increasing the throughput, or the precision, or both the precision and the throughput, of a flow cytometer, or of a hematology analyzer employing a flow cytometer, by utilizing the technique of laser rastering. Laser rastering involves sweeping a laser beam across a flowing sample stream in a hematology analyzer. An apparatus suitable for carrying out the method of this invention comprises an optical module comprising a source of light, a scanning device, a lens or system of lenses, a flow cell, detectors, and filters; and an electronic module comprising preamplifiers, analog signal conditioning elements, analog-to-digital converters, field-programmable gate arrays, digital signal processing elements, and data storage elements. | 09-22-2011 |
| 20110223176 | BASIGIN BINDING PROTEINS - Isolated binding proteins, e.g., antibodies, which bind to Basigin (BSG), e.g., human BSG2, and related antibody-based compositions and molecules are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, as well as therapeutic and diagnostic methods for using the antibodies. | 09-15-2011 |
| 20110218214 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme - The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action. | 09-08-2011 |
| 20110218150 | ANTIANGIOGENIC POLYPEPTIDES AND METHODS FOR INHIBITING ANGIOGENESIS - Conjugated kringle protein fragments are disclosed as compounds for treating angiogenic diseases. Methods and compositions for inhibiting angiogenic diseases are also disclosed. | 09-08-2011 |
| 20110217237 | THERAPEUTIC DLL4 BINDING PROTEINS - DLL4 binding proteins are described herein, including antibodies, CDR-grafted antibodies, humanized antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 and/or VEGF activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis. | 09-08-2011 |
| 20110212094 | DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF - The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease. | 09-01-2011 |
| 20110208292 | HINGED SHEATH ASSEMBLY AND METHOD OF USE - A sheath assembly is provided for protecting a stent mounted on a catheter. An inner tubular member is positioned over the stent without longitudinal movement of the inner tubular member along the stent surface thereby eliminating the possibility of scraping or scratching a drug coating or polymer coating on the stent surface. An outer tubular member slides over the inner tubular member to firmly compress it onto the stent for further protection. In use, the outer tubular member is removed from over the inner tubular member so that the inner tubular member can open similar to a clamshell opening radially outwardly away from the stent without longitudinal movement along the stent surface. | 08-25-2011 |
| 20110207704 | Novel Oxadiazole Compounds - Novel oxadiazole compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions as agonists or antagonists of the S1P family of G protein-coupled receptors for treating diseases associated with modulation of S1P family receptor activity, in particular by affording a beneficial immunosuppressive effect are disclosed. | 08-25-2011 |
| 20110207143 | DIAGNOSTIC TEST FOR MUTATIONS IN CODONS 12-13 OF HUMAN K-RAS - The invention is directed to compositions, methods and kits for diagnosing cancers and tumors correlated with mutations in codons 12 and 13 of human K-RAS using primers that amplify target sequences. The amplified target sequences are then analyzed by any number of mass spectrometric techniques, which data are queried against a database of base composition signatures of K-RAS mutations in codons 12 and 13. | 08-25-2011 |
| 20110206687 | Isolation And Purification Of Anti-IL-13 Antibodies Using Protein A Affinity Chromatography - Disclosed herein are methods for the isolation and purification of anti-IL-13 antibodies wherein the use of an affinity chromatographic step results in an antibody composition sufficiently pure for pharmaceutical uses. The methods described herein comprise pH viral reduction/inactivation, ultrafiltration/diafiltration, affinity chromatography (e.g., Protein A affinity chromatography), ion exchange chromatography, and hydrophobic chromatography. Further, the present invention is directed toward pharmaceutical compositions comprising one or more antibodies of the present invention. | 08-25-2011 |
| 20110206680 | METHODS FOR TREATING PSORIASIS - The invention provides methods of treating psoriasis in a subject by administering to a subject an antibody capable of binding to the p40 subunit of IL-12 and/or IL-23. | 08-25-2011 |
| 20110201967 | CATHETER DEPLYMENT DEVICE - An apparatus for deploying a needle within a lumen is provided. The apparatus includes a housing having a threaded bushing radially disposed therein. The bushing rigidly couples with a nose cone having a guide tip disposed at an end opposite the bushing for penetrating an arterial wall of a lumen. During operation, a user incrementally advances the bushing within the housing, thereby incrementally advancing the guide tip into the lumen. The nose cone also includes a flex guide having a slot configuration which couples with the guide tip which deploys into the lumen along with the guide tip. | 08-18-2011 |
| 20110201130 | HUMAN B-TYPE NATRIURETIC PEPTIDE ASSAY HAVING REDUCED CROSS-REACTIVITY WITH OTHER PEPTIDE FORMS - The present disclosure provides among other things assays, methods and kits for assessing the presence or amount of human B-type natriuretic peptide in a test sample wherein the assay exhibits reduced cross-reactivity with other forms of the peptide. | 08-18-2011 |
| 20110201060 | PROCESS FOR THE PREPARATION OF SCYLLO-INOSITOL - This invention pertains to a process for manufacturing scyllo-Inositol. Specifically, the current invention pertains to a process for converting myo-Inositol to scyllo-Inositol using a bioconversion process. | 08-18-2011 |
| 20110196387 | VASCULAR SUTURING DEVICE - A surgical device for suturing vascular vessels is described, as well as methods for suturing tissue employing the surgical device. The device includes a distal member for insertion into a vascular vessel puncture wound. The distal member contains a suture and needle engaging fitting. At least one needle is advanced through tissue adjacent the puncture wound and into the needle engaging fitting to draw lengths of suture material which can then be used to close the puncture wound. | 08-11-2011 |
| 20110196010 | CRYSTALLINE CHEMOTHERAPEUTIC - N-[4-(3-Amino-1H-indazol-4-yl)phenyl]-N′-(2-fluoro-5-methylphenyl)urea Hydrate Crystalline Form 1, ways to make it, formulations comprising it and made with it and methods of treating patients having disease using it are disclosed. | 08-11-2011 |
| 20110190540 | Methods for Preparing S1P Receptor Agonists and Antagonists - Disclosed herein are methods of making compounds which are agonists or antagonists of one or more of the individual receptors of the S1P receptor family. | 08-04-2011 |
| 20110190489 | Novel Tricyclic Compounds - The invention provides a compound of Formula (Ia), (Ib), (Ic), (Id), (Ie), (If), (Ig), (Ih), (Ii), (Ij), (Ik), or (Il) as defined herein, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions. | 08-04-2011 |
| 20110190314 | PHARMACEUTICAL COMPOSITIONS AND THEIR METHODS OF USE - The invention relates to a composition comprising a neuronal nicotinic receptor ligand and an α4β2 positive allosteric modulator, a method of using the same, and a related article of manufacture. | 08-04-2011 |
| 20110186570 | CONTAINER - A container ( | 08-04-2011 |
| 20110184509 | DUAL SHEATH ASSEMBLY AND METHOD OF USE - A sheath assembly is provided for protecting a stent mounted on a catheter. An inner tubular member is positioned over the stent without longitudinal movement of the inner tubular member along the stent surface thereby eliminating the possibility of scraping or scratching a drug coating or polymer coating on the stent surface or balloon surface. An outer tubular member slides over the inner tubular member to firmly compress it onto the stent for further protection. In use, the outer tubular member is removed from over the inner tubular member so that the two half-cylindrical portions of the inner tubular member can fall away from the stent without longitudinal movement along the stent surface. | 07-28-2011 |
| 20110178121 | Methods for Treating Pain - The present invention is directed to methods of treating pain by administering a therapeutically effective amount of an α7 nAChR ligand or a pharmaceutically acceptable salt thereof, to a mammal in need of treatment thereof and to pharmaceutical compositions comprising such a compound or salt. | 07-21-2011 |
| 20110178096 | OCTAHYDROPENTALENE COMPOUNDS AS CHEMOKINE RECEPTOR ANTAGONISTS - The present invention is directed to novel compounds of Formula (I) | 07-21-2011 |
| 20110171662 | NON-DENATURING LYSIS REAGENT - The invention provides a lysis reagent and method for preparing a test sample for use in an assay, wherein the method yields a homogeneous lysis mixture suitable for use in automated pipetting systems without the need for a centrifugation step. The lysis reagent includes a glycol and an alcohol. Other aspects of the invention include related immunoassays and test kits. | 07-14-2011 |
| 20110171648 | METHOD OF DETECTING AND QUANTIFYING HEPATITIS C VIRUS - Methods, reagents, and kits for detecting hepatitis C virus (HCV) in biological samples. | 07-14-2011 |
| 20110166250 | COPOLYMERS HAVING ZWITTERIONIC MOIETIES AND DIHYDROXYPHENYL MOIETIES AND MEDICAL DEVICES COATED WITH THE COPOLYMERS - Copolymers are manufactured to include a zwitterionic monomer (e.g., methacryloyloxyethyl phosphorylcholine monomer), a dihydroxyphenyl derivatized monomer, and optionally one or more additional monomers. The dihydroxyphenyl derivatized monomer gives the copolymers excellent adhesion properties. Optional monomers include a cationic amino monomer, a hydrocarbon monomer, and/or a hydrophilic monomer. The copolymers are biocompatible and can be used with medical devices. | 07-07-2011 |
| 20110166171 | SUSTAINED RELEASE MONOEXIMIC FORMULATIONS OF OPIOID AND NONOPIOID ANALGESICS - The present invention relates to monoeximic solid dosage forms for administering pharmaceutical agents, particularly Hydrocodone and acetaminophen, methods for preparing said dosage forms, and methods for providing therapeutic agents to patients in need of treatment. | 07-07-2011 |
| 20110165063 | IL-1 BINDING PROTEINS - The present invention describes IL-1α binding proteins, including chimeric, CDR-grafted, and humanized antibodies that bind IL-1α. Binding proteins of the invention have high affinity for IL-1α and neutralize IL-1α activity. A binding protein of the invention can be a full-length antibody or an IL-1α-binding portion thereof. Methods of making and methods of using the binding proteins of the invention are also described. The IL-1α binding proteins of the invention are useful for detecting IL-1α and for inhibiting IL-1α activity, including in a human subject suffering from a disease or disorder in which IL-1α activity is detrimental. | 07-07-2011 |
| 20110160417 | AMINO ACID MIMETIC COPOLYMERS AND MEDICAL DEVICES COATED WITH THE COPOLYMERS - Biocompatible polymers are manufactured to include an amino acid mimetic monomer and one or more hydrophobic acrylate monomers. The amino acid mimetic monomers are selected to mimic the side chain of the amino acids asparagine or glutamine. The amino acid mimetic monomer can be a methacryloyl or acryloyl derivative of 2-hydroxyacetamide, 3-hydroxypropionamide, alaninamide, lactamide, or glycinamide. These amide functional groups offer the advantage of moderate hydrophilicity with little chemical reactivity. The amino acid mimetic monomer can be copolymerized with one or more hydrophobic acrylate monomers to obtain desired coating properties. | 06-30-2011 |
| 20110160391 | AMINO ACID MIMETIC COPOLYMERS AND MEDICAL DEVICES COATED WITH THE COPOLYMERS - Biocompatible polymers are manufactured to include an amino acid mimetic monomer and one or more hydrophobic acrylate monomers. The amino acid mimetic monomers are selected to mimic the side chain of the amino acids asparagine or glutamine. The amino acid mimetic monomer can be a methacryloyl or acryloyl derivative of 2-hydroxyacetamide, 3-hydroxypropionamide, alaninamide, lactamide, or glycinamide. These amide functional groups offer the advantage of moderate hydrophilicity with little chemical reactivity. The amino acid mimetic monomer can be copolymerized with one or more hydrophobic acrylate monomers to obtain desired coating properties. | 06-30-2011 |
| 20110160382 | COPOLYMERS HAVING ZWITTERIONIC MOIETIES AND DIHDROXYPHENYL MOIETIES AND MEDICAL DEVICES COATED WITH THE COPOLYMERS - Copolymers are manufactured to include a zwitterionic monomer (e.g., methacryloyloxyethyl phosphorylcholine monomer), a dihydroxyphenyl derivatized monomer, and optionally one or more additional monomers. The dihydroxyphenyl derivatized monomer gives the copolymers excellent adhesion properties. Optional monomers include a cationic amino monomer, a hydrocarbon monomer, and/or a hydrophilic monomer. The copolymers are biocompatible and can be used with medical devices. | 06-30-2011 |
| 20110160331 | AMINO ACID MIMETIC COPOLYMERS AND MEDICAL DEVICES COATED WITH THE COPOLYMERS - Biocompatible polymers are manufactured to include an amino acid mimetic monomer and one or more hydrophobic acrylate monomers. The amino acid mimetic monomers are selected to mimic the side chain of the amino acids asparagine or glutamine. The amino acid mimetic monomer can be a methacryloyl or acryloyl derivative of 2-hydroxyacetamide, 3-hydroxypropionamide, alaninamide, lactamide, or glycinamide. These amide functional groups offer the advantage of moderate hydrophilicity with little chemical reactivity. The amino acid mimetic monomer can be copolymerized with one or more hydrophobic acrylate monomers to obtain desired coating properties. | 06-30-2011 |
| 20110160233 | ANTI-VIRAL COMPOUNDS - Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) or other viruses are disclosed. This invention is also directed to compositions comprising such compounds, co-formulation or co-administration of such compounds with other anti-viral or therapeutic agents, processes and intermediates for the syntheses of such compounds, and methods of using such compounds for the treatment of HCV or other viral infections. | 06-30-2011 |
| 20110159085 | ABT-263 CAPSULE - A pharmaceutical capsule comprises a shell having encapsulated therewithin a liquid solution of ABT-263 or a pharmaceutically acceptable salt thereof in a substantially non-ethanolic carrier that comprises as pharmaceutically acceptable excipients (a) at least one phospholipid, (b) at least one solubilizing agent for the at least one phospholipid, selected from the group consisting of glycols, glycerides and mixtures thereof, (c) at least one non-phospholipid surfactant and (d) at least one sulfur-containing antioxidant. The capsule is useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer. | 06-30-2011 |
| 20110159005 | 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11BETA-HSD1) INHIBITORS AND USES THEREOF - A method for treating a patient suffering from inflammation, chronic inflammation, pain, rheumatoid arthritis (RA), osteoarthritis and osteoporosis, comprising administering an effective amount of a selective inhibitor of the 11-β-hydroxysteroid dehydrogenase Type 1 enzyme. | 06-30-2011 |
| 20110154521 | TRANSGENIC ANIMALS EXPRESSING ANTIBODIES SPECIFIC FOR GENES OF INTEREST AND USES THEREOF - The invention provides compositions and methods for the generation of novel non-human transgenic animals which contain an alteration in a gene of interest. These transgenic animals are capable of generating antibodies, e.g., human monoclonal antibodies, specific for the product of a gene of interest that has been functionally disrupted in the transgenic animal. Furthermore, the methods and compositions of the invention are suitable for use in the treatment, diagnosis, and imaging of disease. | 06-23-2011 |
| 20110152336 | COMBINATION THERAPY WITH PARP INHIBITORS - The present invention describes benzimidazole derivatives of Formula (I) which constitute potent PARP inhibitors in combination with radiotherapy or in combination with other chemotherapeutic agents. | 06-23-2011 |
| 20110152325 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS IV - The present invention relates to novel carboxamide compounds and their use for the manufacture of a medicament. The carboxamide compounds are inhibitors of calpain (calcium dependant cysteine proteases). The invention therefore also relates to the use of these carboxamide compounds for treating a disorder associated with an elevated calpain activity. | 06-23-2011 |
| 20110152308 | AZA-RING FUSED INDOLE AND INDOLINE DERIVATIVES - The present application relates to indole and indoline derivatives of formula (I) | 06-23-2011 |
| 20110152306 | AZA-BRIDGED RING-FUSED INDOLES AND INDOLINES - The present application relates to indole and indoline derivatives of formula (I) | 06-23-2011 |
| 20110152265 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS V - The present invention relates to novel carboxamide compounds and their use for the manufacture of a medicament. The carboxamide compounds are inhibitors of calpain (calcium dependant cysteine proteases). The invention therefore also relates to the use of these carboxamide compounds for treating a disorder associated with an elevated calpain activity. | 06-23-2011 |
| 20110152250 | CHROMANYLUREA COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR AND USES THEREOF - Compounds that are antagonists of the VR1 receptor, having formula (I) | 06-23-2011 |
| 20110152248 | BRIDGEHEAD AMINE RING-FUSED INDOLES AND INDOLINES - The present application relates to indole and indoline derivatives of formula (I), formula (II), formula (III), or formula (IV) | 06-23-2011 |
| 20110152243 | NOVEL THIENOPYRROLE COMPOUNDS - The invention provides a compound of Formula (I) | 06-23-2011 |
| 20110151502 | METHOD FOR PERFORMING A BLOOD COUNT AND DETERMINING THE MORPHOLOGY OF A BLOOD SMEAR - A method for counting blood cells in a sample of whole blood. The method comprises the steps of:
| 06-23-2011 |
| 20110151023 | COMBINATION THERAPY WITH PARP INHIBITORS - The present invention describes benzimidazole derivatives of Formula (I) which constitute potent PARP inhibitors in combination with radiotherapy or in combination with other chemotherapeutic agents. | 06-23-2011 |
| 20110150861 | SORF CONSTRUCTS AND MULTIPLE GENE EXPRESSION - Embodiments of the invention relate to vector constructs and methods for expression of polypeptides including multimeric products such as therapeutic antibodies. Particular constructs allow for the generation of expression products from a single open reading frame (sORF). An embodiment provides an isolated or purified expression vector for generating one or more recombinant protein products comprising a single open reading frame insert; said insert comprising a signal peptide nucleic acid sequence encoding a signal peptide; a first nucleic acid sequence encoding a first polypeptide; a first intervening nucleic acid sequence encoding a first protein cleavage site, wherein said first protein cleavage site is provided by an intein segment of a Ion protease gene of | 06-23-2011 |
| 20110150704 | CONTAINER HAVING GAS SCRUBBER INSERT FOR AUTOMATED CLINICAL ANALYZER - A device and method for extending the useful life of a liquid in a container used in an automated clinical analyzer. The liquid comprises a material subject to deterioration, the subject material capable of deteriorating as the result of reaction with a contaminant in a gas present in the atmospheric air surrounding the container. Atmospheric air surrounding the container that displaces the liquid consumed from a container is routed through a gas scrubber insert in order to remove or at least reduce the quantity of at least one contaminant present in that air. The gas scrubber insert is positioned between the liquid in the container and the atmospheric air surrounding the container. The gas scrubber insert contains a reagent that is capable of reacting with a contaminant in the atmospheric air surrounding the container, whereby a required characteristic(s) of the liquid does (do) not change excessively prior to the date that the liquid is consumed. For example, if the contaminant is carbon dioxide, and the required characteristic of the liquid is the level of pH of the liquid, the reagent in the gas scrubber insert prevents the level of pH of the liquid from changing excessively prior to the date that the liquid is consumed. | 06-23-2011 |
| 20110147294 | SYSTEM FOR PROCESSING MAGNETIC PARTICLES - A system for separating a solid magnetic substrate from liquid contents of a reaction vessel, the system comprising at least one micro-well plate having a plurality of rows and a plurality of magnets arranged in at least two rows. In one embodiment, the at least two rows of the plurality of magnets are controlled so as to cause the magnets in the at least two rows of magnets to move in unison. In another embodiment, one row of the at least two rows of the plurality of magnets is controlled so as to cause the magnets in said one row to move at a first velocity in the vertical direction and another row of the at least two rows of the plurality of magnets is controlled so as to cause the magnets in that other row to move at a second velocity in the vertical direction. | 06-23-2011 |
| 20110144343 | PROCESS FOR PREPARING CANNABINOID RECEPTOR LIGANDS - A process for the preparation of compounds of formula (I) or a salt thereof | 06-16-2011 |
| 20110144165 | PRODRUG COMPOUNDS USEFUL AS CANNABINOID LIGANDS - The present invention provides for compounds of formula (I) | 06-16-2011 |
| 20110144057 | ANTAGONISTS OF THE VANILLOID RECEPTOR SUBTYPE 1 (VR1) AND USE THEREOF - The present invention is directed to compounds of formula (I) | 06-16-2011 |
| 20110142845 | NEUTRALIZING MONOCLONAL ANTIBODIES AGAINST THE NOGO-66 RECEPTOR (NgR) AND USES THEREOF - The subject invention relates to isolated proteins, particularly monoclonal antibodies, which bind to the Nogo-66 receptor. Specifically, these antibodies have the ability to inhibit the binding of the natural ligand of the Nogo-66 receptor and neutralize the Nogo-66 receptor. These antibodies or portions thereof of the invention are useful for detecting NgR and for inhibiting NgR activity, for example in a human suffering from a disorder in which NgR or Nogo-66 activity is detrimental. | 06-16-2011 |
| 20110142761 | IL-1 BINDING PROTEINS - The present invention describes IL-1β binding proteins, including chimeric, CDR-grafted, and humanized antibodies that bind IL-1β. Binding proteins of the invention have high affinity for IL-1β and neutralize IL-1β activity. A binding protein of the invention can be a full-length antibody or an IL-1β-binding portion thereof. Methods of making and methods of using the binding proteins of the invention are also described. The IL-1β binding proteins of the invention are useful for detecting IL-1β and for inhibiting IL-1β activity, including in a human subject suffering from a disease or disorder in which IL-1β activity is detrimental. | 06-16-2011 |
| 20110137633 | ANTI-VIRAL COMPOUNDS AND METHODS OF IDENTIFYING THE SAME - Methods of identifying NS5A inhibitors are provided. Novel binding sites are identified on NS5A dimers, and these binding sites can be used to design and/or identify new NS5A inhibitors. | 06-09-2011 |
| 20110137015 | Markers of XMRV Infection and Uses Thereof - The present invention relates generally to assays for the detection of Xenotropic Murine Leukemia Virus-related Retrovirus (“XMRV”) and diseases associated with XMRV infection. Additionally, the invention relates to specific XMRV antigens capable of inducing an immunogenic response as well as XMRV-related nucleic acids having significant diagnostic, screening, and therapeutic utilities. | 06-09-2011 |
| 20110136256 | METHODS AND KITS FOR DECREASING INTERFERENCES IN PLASMA OR SERUM CONTAINING ASSAY SAMPLES OF SPECIFIC BINDING ASSAYS - Methods and kits are provided for decreasing interferences and inaccuracies due to nonoptimal sample handling of blood samples in plasma or serum containing assay samples of specific binding assays by addition of a large polycation to the assay sample during the specific binding assay. | 06-09-2011 |
| 20110136141 | PEPTIDE REAGENTS AND METHOD FOR INHIBITING AUTOANTIBODY ANTIGEN BINDING - The present disclosure provides immunoassays and kits for detection or quantification of an protein of interest in a test sample that potentially contains endogenously produced autoantibodies reactive with the analyte. | 06-09-2011 |
| 20110136103 | AUTOANTIBODY ENHANCED IMMUNOASSAYS AND KITS - The present disclosure provides immunoassays and kits for detection or quantification of an analyte of interest in a test sample that potentially contains endogenously produced autoantibodies reactive with the analyte. | 06-09-2011 |
| 20110135674 | Markers of XMRV Infection and Uses Thereof - The present invention relates generally to assays for the detection of Xenotropic Murine Leukemia Virus-related Retrovirus (“XMRV”) and diseases associated with XMRV infection. Additionally, the invention relates to specific XMRV antigens capable of inducing an immunogenic response as well as XMRV-related nucleic acids having significant diagnostic, screening, and therapeutic utilities. | 06-09-2011 |
| 20110130382 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF - The present application relates to 1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,4]benzodiazepine, 1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1,5]benzodiazepine, 2,3,4,4a,5,6,7,11b-octahydro-1H-pyrido[3,4-d][2]benzazepine, 1,2,3,4,4a,5,6,7-octahydropyrazino[1,2-a][1]benzazepine, 1,2,3,4,4a,5-hexahydro-7H-pyrazino[1,2-a][4,1]benzoxazepine, and 2,3,4,4a,5,6-hexahydro-1H-pyrazino[2,1-d][1,5]benzoxazepine, and 5,6,7,7a,8,9,10,11-octahydropyrazino[1,2-d]pyrido[3,2-b][1,4]diazepine derivatives of formula (I) | 06-02-2011 |
| 20110130295 | Diagnostic Methods For Determining Prognosis Of Non-Small Cell Lung Cancer - Disclosed are methods for identifying early-stage non-small-cell lung cancer (NSCLC) patients who will have an unfavorable prognosis for the recurrence of lung cancer after surgical resection. The methods are based in part on the discovery that chromosomal copy number gains at Chr19, 34.7 Mb-35.6 Mb can be used for prognostic classification. The methods preferably use fluorescence in situ hybridization with fluorescently labeled nucleic acid probes to hybridize to patient samples to quantify the chromosomal copy number of this genetic locus. | 06-02-2011 |
| 20110129854 | ASSAY FOR DIAGNOSIS OF CARDIAC MYOCYTE DAMAGE - Assays are disclosed for diagnosing a clinical condition, assessing risk or predicting an outcome as a result of cardiac myocyte damage. Immunoassay methods and kits provide for the assessment of cardiac myocyte damage by determining the presence of multiple cardiac myocyte antigens in a test sample, and combining the multiple determinations in a single assay result. | 06-02-2011 |
| 20110129818 | ASSAY FOR CARDIAC TROPONIN-T (cTnT) - The present disclosure describes immunoassays for detecting cardiac troponin-T (cTnT) in a test sample, and in particular immunoassays and kits for detecting cTnT in a test sample suspected of containing substances that may interfere with the determination of cTnT, such as heterophilic endogenous antibodies and autoantibodies to cTnT. The methods use more than one capture phase antibody and more than one detection antibody to improve specificity, and provide for the use of humanized immunoreagents to overcome heterophilic antibody interferences. | 06-02-2011 |
| 20110124676 | BIARYL SUBSTITUTED AZABICYCLIC ALKANE DERIVATIVES - The invention relates to biaryl substituted azabicyclic alkane derivatives, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions. | 05-26-2011 |
| 20110124642 | POTASSIUM CHANNEL MODULATORS - Disclosed herein are KCNQ potassium channels modulators of formula (I) | 05-26-2011 |
| 20110124632 | IMIDAZOPYRIDINES AS A NOVEL SCAFFOLD FOR MULTI-TARGETED KINASE INHIBITION - Compounds that inhibit protein kinases, compositions containing the compounds and methods of treating diseases using the compounds are disclosed. | 05-26-2011 |
| 20110124628 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES - Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein. | 05-26-2011 |
| 20110124012 | ASSAYS FOR HUMAN NT-PRO B-TYPE NATRIURETIC PEPTIDE, HUMAN PRO B-TYPE NATRIURETIC PEPTIDE AND HUMAN B-TYPE NATRIURETIC PEPTIDE - The present disclosure relates to assays for detecting and/or quantifying the amount of human NT-pro B-type natriuretic peptide, human pro B-type natriuretic peptide and human B-type natriuretic peptide in a test sample. | 05-26-2011 |
| 20110123702 | ROOM TEMPERATURE-CURABLE POLYMERS - Methods of making room temperature-curable polymers. Reactants include siloxane-terminated polymers and silanols. The reactants are mixed, and the polymerization allowed to proceed in air at room temperature. The polymers are exceptionally useful because they allow for the incorporation into the polymers themselves of one or more therapeutic compounds. Thus, medical devices from which controlled drug release is desirable (for either local or systemic delivery) can be coated with therapeutic compound-containing polymers of the invention. In a preferred embodiment, a polymer of poly(MPC | 05-26-2011 |
| 20110118301 | Amino-Aza-Adamantane Derivatives and Methods of Use - The invention relates to amine-substituted aza-adamantane derivatives, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions. | 05-19-2011 |
| 20110118231 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF - The present application relates to aryl- and heteroaryl-fused decahydropyrroloazepine, octahydrooxepinopyrrole, octahydropyrrolothiazepine dioxide, decahydrocyclohepta[c]pyrrole, and octahydrocyclohepta[c]pyrrole derivatives of formula (I) | 05-19-2011 |
| 20110117603 | ENHANCEMENT OF CELLULAR PRODUCTION THROUGH MECHANOTRANSDUCTION - Disclosed herein are methods of modulating protein production via the application of tensegrity forces on cells and cell cultures. The methods of the invention increase production of protein from cells and cell culture. The tensegrity forces can be stress that is applied to the cells, and can include one or more of the following: mechanical stress, shear stress, stretch effects, and pressure induced stress. | 05-19-2011 |
| 20110117079 | THERAPEUTIC DLL4 BINDING PROTEINS - Improved DLL4 binding proteins are described, including antibodies, CDR-grafted antibodies, human antibodies, and DLL4 binding fragments thereof, proteins that bind DLL4 with high affinity, and DLL4 binding proteins that neutralize DLL4 activity. The DLL4 binding proteins are useful for treating or preventing cancers and tumors and especially for treating or preventing tumor angiogenesis, and/or other angiogenesis-dependent diseases such as ocular neovascularization, or angiogenesis-independent diseases characterized by aberrant DLL4 expression or activity such as autoimmune disorders including multiple sclerosis. | 05-19-2011 |
| 20110112624 | Avoiding Stress-Induced Martensitic Transformation in Nickel Titanium Alloys Used in Medical Devices - A process for assembling a medical device made from a nickel-titanium alloy for use in a mammalian body while avoiding the formation of stress-induced martensite and a medical device used in combination with a delivery system for deployment into the mammalian body are disclosed. By heating the nickel-titanium alloy of the medical device to a temperature above M | 05-12-2011 |
| 20110106138 | EXPANDABLE EMBOLI FILTER AND THROMBECTOMY DEVICE - Expandable emboli filter and thrombectomy devices adapted for use with microcatheters to remove debris from blood vessels. The devices embody expanded profiles that span the entirety of various sized target vessels and thus are particularly effective in the engagement of debris found in vessels. | 05-05-2011 |
| 20110106104 | SNARED SUTURE TRIMMER - A suture trimmer having a shaft, a cutting member, an actuating device, and a snare. The shaft has a first end and a second end and bounds a bore extending from the first end toward the second end. The shaft has an opening formed in a side adjacent the first end. The cutting member is slidably disposed within the bore of the shaft and can be moved between a first position and a second position, such that when disposed in the second position the cutting member closes the opening formed in the side of the shaft. The actuating device is in communication with the cutting member and is operable to move the cutting member from the first position to the second position. The snare extends through the opening and out of the bore at the first end of the shaft. | 05-05-2011 |
| 20110105502 | TETRAHYDROISOQUINOLINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY - The present invention relates to tetrahydroisoquinoline of the formula (I) | 05-05-2011 |
| 20110105476 | SUBSTITUTED 7,8-DIHYDRO-1HPYRIMIDO[4,5-B]DIAZEPIN-4-AMINES ARE NOVEL KINASE INHIBITORS - Compounds having the Formula (I) | 05-05-2011 |
| 20110105341 | Diagnostic Methods For Determining Prognosis Of Non-Small Cell Lung Cancer - The present disclosure provides methods for identifying early stage non-small-cell lung cancer (NSCLC) patients who will have an unfavorable prognosis for the recurrence of lung cancer after surgical resection. The methods are based in part on the discovery of chromosomal copy number abnormalities that can be used for prognostic classification. The methods preferably use fluorescence in situ hybridization with fluorescently labeled nucleic acid probes to hybridize to patient samples to quantify the chromosomal copy number of these genetic loci. | 05-05-2011 |
| 20110104174 | ANTIBODIES TO RECEPTOR FOR ADVANCED GLYCATION END PRODUCTS (RAGE) AND USES THEREOF - The present application relates to antibodies, such as monoclonal antibodies, and in particular CDR grafted, humanized versions thereof, for the treatment and diagnosis of pain and other neuroinflammatory conditions associated with the Receptor for Advanced Glycation End Products (RAGE). | 05-05-2011 |
| 20110098285 | BICYCLIC-SUBSTITUTED AMINES AS HISTAMINE-3 RECEPTOR LIGANDS - Compounds of formula (I) | 04-28-2011 |
| 20110092445 | Amyloid peptide analogues, oligomers thereof, processes for preparing and composi-tions comprising said analogues or oligomers, and their uses - The present invention relates to an amyloid β peptide analogues comprising an amino acid sequence or a peptidomimetic thereof, wherein the sequence (i) forms a loop, (ii) has at least 66% identity to the amino acid sequence of native Aβ peptide or a portion thereof, (iii) comprises at least 6 contiguous amino acid residues and (iv) has at least 2 non-contiguous amino acid residues which are covalently linked with each other, oligomers comprising a plurality of said amyloid β peptide analogues, processes for preparing the amyloid β peptide analogues or oligomers, compositions comprising the amyloid β peptide analogues or oligomers, and uses of the amyloid β peptide analogues or oligomers such as their use for treating or preventing an amyloidosis (e.g. by active immunization), for diagnosing an amyloidosis, and for providing agents that are capable of binding to the amyloid β peptide analogues or oligomers. The subject invention also describes agents that are capable of binding to the amyloid β peptide analogues or oligomers, e.g. antibodies, compositions comprising the agents, and uses of the agents such as their use for treating or preventing an amyloidosis (e.g. by passive immunization) and for diagnosing an amyloidosis. | 04-21-2011 |
| 20110091997 | IMMUNOSUPPRESSANT DRUG EXTRACTION REAGENT FOR IMMUNOASSAYS - An improved extractive reagent composition and method for extracting an immunosuppressant drug, such as sirolimus, tacrolimus or cyclosporine, from blood samples while yielding a test sample extract that has low vapor pressure and is compatible with immunoassay components. The inventive reagent composition comprises dimethyl sulfoxide (DMSO), at least one divalent metal salt and water. The sample extracts resulting from use of each of these combinations have low vapor pressure and are compatible with immunochemistry assays. | 04-21-2011 |
| 20110091868 | NOVEL ANTIGEN CONSTRUCTS USEFUL IN THE DETECTION AND DIFFERENTIATION OF ANTIBODIES TO HIV - Isolated HIV-1 Group O env polypeptides obtained from the HIV-1 isolate HAM112 are claimed, as well as (a) antigen constructs comprising fusions of one or more of each of HIV-1 Group O env polypeptides and HIV-1 Group M env polypeptide and (b) further antigen constructs containing additional Group O sequences and especially the gp41 IDR of isolate HAM112. Also claimed are polynucleotide sequences encoding the above, expression vectors comprising the same, host cells transformed thereby, and immunoassay methods and kits utilizing the antigen constructs of the invention. | 04-21-2011 |
| 20110091463 | Dual Variable Domain Immunoglobulins and Uses Thereof - The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease. | 04-21-2011 |
| 20110091423 | COMPOSITIONS AND METHODS OF USE OF RITONAVIR FOR TREATING HCV - The present invention discloses compositions and a method of improving the pharmacokinetics of pharmaceutical agents (or pharmaceutically acceptable salts, esters, and prodrugs thereof) which are metabolized by cytochrome P450 monoxygenase comprising coadministering ritonavir or a pharmaceutically acceptable salt, ester, and prodrug thereof. | 04-21-2011 |
| 20110091372 | Dual Variable Domain Immunoglobulins and Uses Thereof - The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease. | 04-21-2011 |
| 20110086879 | CARBOXAMIDE COMPOUNDS AND THEIR USE AS CALPAIN INHIBITORS - The present invention relates to novel carboxamide compounds and their use for the manufacture of a medicament. The carboxamide compounds are inhibitors of calpain (calcium dependant cysteine proteases). The invention therefore also relates to the use of these carboxamide compounds for treating a disorder associated with an elevated calpain activity. | 04-14-2011 |
| 20110086863 | BENZENESULFONANILIDE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR - The present invention relates to novel benzenesulfonanilide compounds of the formulae I and I′ and physiologically tolerated acid addition salts and the N-oxides thereof. The compounds possess valuable therapeutic properties and are particularly suitable, for treating diseases that respond to modulation of the serotonin 5-HT | 04-14-2011 |
| 20110086855 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF - The present invention relates to compounds of formula (I), or pharmaceutically acceptable salts, prodrugs, salts of prodrugs, or combinations thereof, | 04-14-2011 |
| 20110086838 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS - The present invention relates to thiophene containing compounds of formula (I) | 04-14-2011 |
| 20110086832 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS - The present application relates to thiazolylidene containing compounds of formula (I) | 04-14-2011 |
| 20110082170 | THIENOPYRIDYL COMPOUNDS THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) AND USES THEREOF - The present invention discloses fused thienopyridyl compounds of general formula (I) | 04-07-2011 |
| 20110082116 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS - The present application relates to isothiazolylidene containing compounds of Formula (I) | 04-07-2011 |
| 20110082097 | AMINO ACID COMPOSITION FOR IMPROVING GLUCOSE TOLERANCE - Disclosed are compositions, including low-calorie beverages or liquids, comprising isoleucine, leucine, valine, cysteine, and methionine, in specified amounts, weight ratios, or both. The compositions are especially useful in treating individuals afflicted with impaired glucose tolerance or diabetes. | 04-07-2011 |
| 20110077670 | ARTICULATING SUTURING DEVICE AND METHOD - Devices, systems, and methods for suturing of body lumens allow the suturing of vascular puncture sites located at the distal end of a percutaneous tissue tract. An elongated articulated foot is inserted through a penetration and actuated extend the foot carrying suturing attachment cuffs. Needles are advanced from the shaft through the vessel wall outside of the penetration and into engagement with the needle cuffs after the foot has been drawn proximally up against the endothelial surface of the blood vessel. The cuffs lockingly engage the needles and can be withdrawn along the needle paths and through the tissue tract to form a loop of suture across the puncture. The articulating foot may be realigned with the shaft and withdrawn proximally through the tissue tract without dilating the tissue tract. | 03-31-2011 |
| 20110071567 | ARTICULATING SUTURING AND DEVICE AND METHOD - Devices, systems, and methods for suturing of body lumens allow the suturing of vascular puncture sites located at the distal end of a percutaneous tissue tract. An elongated articulated foot near a distal end of a shaft is inserted through the penetration and actuated so that the foot extends along the lumenal axis. The foot carries suturing attachment cuffs, and needles are advanced from the shaft through the vessel wall outside of the penetration and into engagement with the needle cuffs after the foot has been drawn proximally up against the endothelial surface of the blood vessel. The cross-section of the shaft within the tissue tract can be minimized by laterally deflecting the needles as they leave the shaft, while tapered depressions within the foot can guide the advancing needles into engagement with the cuffs. The cuffs lockingly engage the needles and can be withdrawn proximally along the needle paths and through the tissue tract so as to form a loop of suture across the puncture. The articulating foot may be realigned with the shaft and withdrawn proximally through the tissue tract without dilating the tissue tract. | 03-24-2011 |
| 20110071552 | ARTICULATING SUTURING DEVICE AND METHOD - Devices, systems, and methods for suturing of body lumens allow the suturing of vascular puncture sites located at the distal end of a percutaneous tissue tract. An elongated articulated foot of the device can be inserted through the penetration and actuated so that the foot extends along the lumenal axis. The foot can carry suturing attachment cuffs with one end of the cuff adapted to receive a needle, while the other end receives suture. A portion of the foot and/or lumen of the shaft can receive a portion of the suture and can include friction reducing structure that aid with movement of the sutured during removal of the cuffs from within the penetration. | 03-24-2011 |
| 20110071472 | SYSTEMS FOR ANCHORING A MEDICAL DEVICE IN A BODY LUMEN - A system for securing a device in tissue, having a sheath having a plurality of side openings; a rotatable element disposed within the sheath; and a plurality of curved projections extending from the rotatable element, wherein rotation of the rotatable element within the sheath pushes distal ends of each of the curved projections outwardly through one of the plurality of openings and into the tissue. | 03-24-2011 |
| 20110071151 | ABT-263 CRYSTALLINE FORMS - ABT-263 free base and crystalline forms thereof are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer. | 03-24-2011 |
| 20110070193 | Anti-Infective Agents and Uses Thereof - This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions. | 03-24-2011 |
| 20110066184 | ARTICULATING SUTURING DEVICE AND METHOD - Devices, systems, and methods for suturing of body lumens allow the suturing of vascular puncture sites located at the distal end of a percutaneous tissue tract. An elongated articulated foot near a distal end of a shaft is inserted through the penetration and actuated so that the foot extends along the lumenal axis. The foot carries suturing attachment cuffs, and needles are advanced from the shaft through the vessel wall outside of the penetration and into engagement with the needle cuffs after the foot has been drawn proximally up against the endothelial surface of the blood vessel. The cross-section of the shaft within the tissue tract can be minimized by laterally deflecting the needles as they leave the shaft, while tapered depressions within the foot can guide the advancing needles into engagement with the cuffs. The cuffs lockingly engage the needles and can be withdrawn proximally along the needle paths and through the tissue tract so as to form a loop of suture across the puncture. The articulating foot may be realigned with the shaft and withdrawn proximally through the tissue tract without dilating the tissue tract. | 03-17-2011 |
| 20110066164 | MODULAR CLIP APPLIER - An apparatus for placement into an opening formed in a wall of a body lumen to deploy a closure element. The apparatus comprising a housing having a handle portion formed at a distal end, the handle portion configured to be engaged by a user when advancing the housing to deploy the closure element. A triggering element deploys the closure device and can at least be partially formed in the housing. A throw reducing mechanism can slide relative to the housing and reduce the distance a user must stretch a hand to move a triggering system within the housing. The housing can include, or be connected to, a handle member having one or more expansion members which expand to provide a stable base for manipulating the apparatus. | 03-17-2011 |
| 20110065930 | PROCESS FOR THE SYNTHESIS OF (2S,3AR,7AS)-OCTAHYDRO-1H-INDOLE CARBOXYLIC ACID AS AN INTERMEDIATE FOR TRANDOLAPRIL - A process for the preparation of (2S,3aR,7aS)-octahydro-1H-indole-20carboxylic acid hydrochloride. | 03-17-2011 |
| 20110065685 | NOVEL INDOLES ARE CANNABINOID RECEPTOR LIGANDS - The present invention provides novel compounds of Formula (I) | 03-17-2011 |
| 20110062352 | DEVICE FOR USE IN NORMALIZING READINGS ON A TESTING MACHINE - An optic module verification device for normalizing between X photon counters, including a verification tray with X verification wells and a modular photon emitter in each verification well. Each photon emitter includes a spring, a Beta source disk, a scintillator disk adjacent the Beta source disk, and a neutral density filter over the scintillator disk, all of which are encapsulated in a cylindrical chamber with the filter adjacent an opening on one end of the chamber and the spring biasing the Beta source disk and the scintillator disk toward the opening. The device is periodically used for normalization, and may be updated when emitted photons fall below a desired level by replacing the scintillator disk and then determining a new normalized reference values for each photon emitter. | 03-17-2011 |
| 20110060400 | VISIBLE ENDOPROSTHESIS - A crack-resistant endoprosthesis for delivery in a body lumen can be comprised of a multilayered material. The multilayered material can include at least two layers having a boundary layer therebetween. The boundary layer is configured to inhibit cracks from propagating from a first layer-to a second layer. The different layers can be comprised of the same materials or different materials. It can be preferred that the multilayered material have layers that are comprised of resiliently-flexible materials, shape memory materials, and/or radiopaque materials. | 03-10-2011 |
| 20110059983 | USE OF SUBSTITUTED OXINDOLE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF PAIN - The present invention relates to the use of substituted oxindole derivatives of formula I as defined in the claims and description for the treatment or prophylaxis of pain. | 03-10-2011 |
| 20110054492 | MEDICAL DEVICE FOR REPAIRING A FISTULA - A closure element applying medical device for repairing a fistula is described. The closure element applying medical device can be configured for repairing any type of fistula that provides an abnormal channel from one body part to another body part (e.g., organ to organ, organ to vessel, and/or vessel to vessel). Examples of fistulas that can be repaired with the present invention include anorectal fistulas, enteroenteral fistulas, enterocutaneous fistulas, vesicovaginal fistulas, arteriovenous fistulas, perilymph fistulas, rectovaginal fistulas, ureterocolon fistulas, and the like. The medical device can include a closure element, a shaft, a carrier assembly, and controller systems. The medical device can also include a locator assembly. Additionally, the closure element applying medical device can include endoscope components so as to function also as an endoscope. | 03-03-2011 |
| 20110053206 | METHOD OF USING LIGAND-FREE LYSING AGENT IN HEMOGLOBIN ANALYSIS - Lysing agents that are free of ligands, including cyanide, for binding hemoglobin for hematology analyzers. The ligand-free lysing agents achieve accurate quantification of hemoglobin parameters, thereby replacing existing lysing agents for analysis of hemoglobin. | 03-03-2011 |
| 20110053179 | Biomarkers For Prediction Of Major Adverse Cardiac Events And Uses Thereof - The present invention relates to combinations of biomarkers and levels thereof that may be used, for example, in the determination of risk associated with the occurrence of a major adverse cardiac event (MACE) in a patient. | 03-03-2011 |
| 20110044980 | Dual Variable Domain Immunoglobulins and Uses Thereof - The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease. | 02-24-2011 |
| 20110040370 | ENDOPROSTHESES FOR PERIPHERAL ARTERIES AND OTHER BODY VESSELS - An endoprostheses for implanting in a body lumen, such as a coronary artery, peripheral artery, or other body lumen includes a plurality of elongate strut members spaced apart and extending along a longitudinal axis, each elongate strut member having a plurality of alternating peaks and valley. At least one flexible connecting link connects each elongate strut member to an adjacent elongate strut member. The elongate strut members and connecting links forming a generally tubular stent body having a first delivery diameter and a second implanted diameter. The positioning of the connecting links along the stent body produces desired stent performance characteristics. | 02-17-2011 |
| 20110040102 | PROCESS FOR THE PREPARATION OF INDAZOLYL UREAS THAT INHIBIT VANILLOID SUBTYPE 1 (VR1) RECEPTORS - The present invention relates to a process of preparing indazolyl ureas that are useful as antagonists of the vanilloid receptor subtype 1 (VR1). | 02-17-2011 |
| 20110034802 | SYSTEMS, METHODS, AND APPARATUS FOR IMAGING AN IMPLANTABLE DEVICE AND METHODS FOR MANUFACTURING - A method for imaging an implantable device is described. The method may include positioning an implantable device within a patient. Ultrasonic energy may be transmitted toward the implantable device. The returning ultrasonic energy may be analyzed to determine a first characteristic of the implantable device. A method for manufacturing an implantable device is also described. The method may include selecting a first size dimension for a plurality of ultrasonically visible portions. The method may further include selecting a first spacing dimension for the plurality of ultrasonically visible portions. An implantable device may be formed. The plurality of ultrasonically visible portions may be formed into the first outer surface. An implantable device is also described. The implantable device may include a first outer surface. The first outer surface may include a first ultrasonically visible portion having a first size dimension. | 02-10-2011 |
| 20110034368 | Multiple Gene Expression Including sORF Constructs and Methods with Polyproteins, Pro-Proteins and Proteolysis - Disclosed are useful constructs and methods for the expression of proteins using primary translation products that are processed within a recombinant host cell. Constructs comprising a single open reading frame (sORF) are described for protein expression including expression of multiple polypeptides. A primary translation product (a pro-protein or a polyprotein) contains polypeptides such as inteins or hedgehog family auto-processing domains, or variants thereof, inserted in frame between multiple protein subunits of interest. The primary product can also contain cleavage sequences such as other proteolytic cleavage or protease recognition sites, or signal peptides which contain recognition sequences for signal peptidases, separating at least two of the multiple protein subunits. The sequences of the inserted auto-processing polypeptides or cleavage sites can be manipulated to enhance the efficiency of expression of the separate multiple protein subunits. Also disclosed are independent aspects of conducting efficient expression, secretion, and/or multimeric assembly of proteins such as immunoglobulins. Where the polyprotein contains immunoglobulin heavy and light chain segments or fragments capable of antigen recognition, in an embodiment a selectable stoichiometric ratio is at least two copies of a light chain segment per heavy chain segment, with the result that the production of properly folded and assembled functional antibody is made. Modified signal peptides, including such from immunoglobulin light chains, are described. | 02-10-2011 |
| 20110016585 | NOVEL DELTA9-ELONGASE FOR PRODUCTION OF POLYUNSATURATED FATTY ACID-ENRICHED OILS - The present disclosure relates to isolated polynucleotides encoding a delta 9-elongase, delta 9-elongases encoded by the isolated polynucleotides, expression vectors comprising the isolated polynucleotides, host cells comprising the expression vectors, and methods for producing delta 9-elongase and polyunsaturated fatty acids. | 01-20-2011 |
| 20110015216 | Solid Pharmaceutical Dosage Form - A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50° C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10. | 01-20-2011 |
| 20110015173 | PYRROLOPYRIDINE INHIBITORS OF KINASES - The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, | 01-20-2011 |
| 20110015172 | PYRROLOPYRAZINE INHIBITORS OF KINASES - The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, | 01-20-2011 |
| 20110009618 | METHODS OF MANUFACTURING CRYSTALLING FORMS OF RAPAMYCIN ANALOGS - A process for preparing a crystalline rapamycin analog includes: combining the rapamycin analog with an organic medium to form a mixture; incubating the mixture until the rapamycin analog crystallizes; and recovering the crystalline rapamycin analog. The organic medium can be a solvent, and the process can include causing the rapamycin analog to dissolve into the solvent, and incubating the solvent until the rapamycin analog crystallizes. The following can also be performed: forming a slurry of crystalline rapamycin analog; stirring the rapamycin analog mixture until the rapamycin analog crystallizes; saturating the rapamycin analog solution; forming a supersaturated rapamycin analog solution; combining an antisolvent with the rapamycin analog and the solvent to form a biphasic mixture, and incubating the biphasic mixture to cause a liquid-liquid phase split. | 01-13-2011 |
| 20110009325 | CRYSTALLINE FORMS OF RAPAMYCIN ANALOGS - Provided is a rapamycin analog composition including a crystalline form of a rapamycin analog. The crystal can be a hydrate. dehydrate, solvate, or desolvate. The rampamycin analog can have a structure of Formula 1, which is optionally a prodrug, salt, derivative, or combination thereof: | 01-13-2011 |
| 20110008766 | Dual Variable Domain Immunoglobulins and Uses Thereof - Engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease. | 01-13-2011 |
| 20110008430 | Solid Pharmaceutical Dosage Form - A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50° C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10. | 01-13-2011 |
| 20110008357 | ANTIBODIES THAT BIND IL-18 AND METHODS OF INHIBITING IL-18 ACTIVITY - Antibodies that bind human interleukin-18 (hIL-18) are provided, in particular antibodies that bind epitope(s) of human IL-18. The antibodies can be, for example, entirely human antibodies, recombinant antibodies, or monoclonal antibodies. Preferred antibodies have high affinity for hIL-18 and neutralize hIL-18 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-18 and for inhibiting hIL-18 activity, e.g., in a human subject suffering from a disorder in which hIL-18 activity is detrimental. | 01-13-2011 |
| 20110004294 | FATIGUE-RESISTANT STENT - A fatigue-resistant implantable medical device. The fatigue-resistant implantable medical device includes a tubular stent. The tubular stent can have a laser-cut length and a shape-set length that is either longer or shorter than the laser-cut length. Such stents will tend to return to their laser-cut length when they are compressed for delivery. A stent that is shape-set longer than its laser-cut/delivery length that is deployed in a vessel that is shortened for stent delivery will tend to return to its shape-set length when the vessel returns to its neutral (i.e., elongated) length. Likewise, a stent that is shape-set shorter than its laser-cut/delivery length that is deployed in a vessel that is elongated for stent delivery will tend to return to its shape-set length when the vessel returns to its neutral (i.e., shortened) length. Such stents will experience reduced axial loading and reduced mean strain, thereby improving fatigue life. | 01-06-2011 |
| 20110004238 | INTRAVASCULAR DEVICE AND SYSTEM - A device for use in capturing or collecting debris found in blood vessels or other body lumens. The devices can be fabricated from a tube and include longitudinally and circumferentially extending members. The device can further embody structure that provides enhanced radial opening and angular resistance to collapse and structure for absorbing or modifying forces applied thereto by an operator. | 01-06-2011 |
| 20110003971 | MODULATORS AND MODULATION OF THE INTERACTION BETWEEN RGM AND NEOGENIN - This invention relates to drug screening using mammalian repulsive guidance molecules and mammalian Neogenin. In addition, the invention provides for methods of preventing, alleviating or treating various disorders of the nervous system, angiogenic disorders or disorders of the cardio-vascular system and malignancies of different etiology by disrupting the interaction between RGM and Neogenin. | 01-06-2011 |
| 20110003360 | DELTA-6 DESATURASE AND USES THEREOF - The subject invention relates to the identification of genes involved in the desaturation of polyunsaturated fatty acids at carbon 5 (i.e., “Δ5-desaturase”) and at carbon 6 (i.e., “Δ6-desaturase”) and to uses thereof. In particular, Δ5-desaturase may be utilized, for example, in the conversion of dihomo-γ-linolenic acid (DGLA) to arachidonic acid (AA) and in the conversion of 20:4n-3 to eicosapentaenoic acid (EPA). Delta-6 desaturase may be used, for example, in the conversion of linoleic (LA) to γ-linolenic acid (GLA). AA or polyunsaturated fatty acids produced therefrom may be added to pharmaceutical compositions, nutritional compositions, animal feeds, as well as other products such as cosmetics. | 01-06-2011 |
| 20110003351 | DELTA-5 DESATURASE AND USES THEREOF - The subject invention relates to the identification of genes involved in the desaturation of polyunsaturated fatty acids at carbon 5 (i.e., “Δ5-desaturase”) and at carbon 6 (i.e., “Δ6-desaturase”) and to uses thereof. In particular, Δ5-desaturase may be utilized, for example, in the conversion of dihomo-γ-linolenic acid (DGLA) to arachidonic acid (AA) and in the conversion of 20:4n-3 to eicosapentaenoic acid (EPA). Delta-6 desaturase may be used, for example, in the conversion of linoleic (LA) to γ-linolenic acid (GLA). AA or polyunsaturated fatty acids produced therefrom may be added to pharmaceutical compositions, nutritional compositions, animal feeds, as well as other products such as cosmetics. | 01-06-2011 |
| 20100331353 | 3,9-DIAZASPIRO[5,5]UNDECANE AMIDES AND UREAS AND METHODS OF USE THEREOF - Compounds of formula (I) | 12-30-2010 |
| 20100331294 | 4-SUBSTITUTED-2-AMINO-PYRIMIDINE DERIVATIVES - Compounds of the formula | 12-30-2010 |
| 20100328662 | METHOD AND APPARATUS FOR RAPIDLY COUNTING AND IDENTIFYING BIOLOGICAL PARTICLES IN A FLOW STREAM - A method for increasing the throughput, or the precision, or both the precision and the throughput, of a flow cytometer, or of a hematology analyzer employing a flow cytometer, by utilizing the technique of laser rastering. Laser rastering involves sweeping a laser beam across a flowing sample stream in a hematology analyzer. An apparatus suitable for carrying out the method of this invention comprises an optical module comprising a source of light, a scanning device, a lens or system of lenses, a flow cell, detectors, and filters; and an electronic module comprising preamplifiers, analog signal conditioning elements, analog-to-digital converters, field-programmable gate arrays, digital signal processing elements, and data storage elements. | 12-30-2010 |
| 20100324722 | SYSTEM FOR MANAGING INVENTORIES OF REAGENTS - A system for managing the inventory of reagents for a laboratory automation system. The system for managing the inventory of reagents comprises a controller, software for the controller, and a refrigerator capable of refrigerating reagents, detecting the presence or absence of reagents in the refrigerator, and detecting the location of reagents in the refrigerator. The system for managing the inventory of reagents is connected to a laboratory automation system. The laboratory automation system comprises at least one clinical analyzer. A typical system for managing inventories of reagents includes an operator interface for the loading of boxes of reagents and other supplies, radio frequency identification system for identification of inventory and tracking, robotic mechanisms for loading containers onto the track system and removing containers from the track system, de-capping equipment, refrigeration equipment, and information technology connections to laboratory analyzers and vendors. | 12-23-2010 |
| 20100324598 | MULTI ELEMENT BIASED SUTURE CLIP - A suture clamp comprising a plurality of elements positioned together in a row, each element of the plurality of elements having a lower portion separated from an upper portion by a flexible neck, each element of the plurality of elements including a slot having an outwardly facing opening, the slots from the plurality of elements configured to accept a suture element through the row of elements and secure the suture element. A method of clamping a suture, including applying a biasing force to at least one element into the first position to provide access to the outwardly facing opening of the slot, passing the suture through a tissue layer, receiving the suture into the slot through the outward facing opening, and removing the biasing force to form a tortuous path between adjacently positioned elements of the plurality of elements. | 12-23-2010 |
| 20100324027 | DIAZAHOMOADAMANTANE DERIVATIVES AND METHODS OF USE THEREOF - The invention relates to compounds that are diazahomoadamantane derivatives, compositions comprising such compounds, and methods of using such compounds and compositions. | 12-23-2010 |
| 20100324018 | PHARMACEUTICAL COMPOSITIONS HAVING IMPROVED DISSOLUTION PROFILES FOR POORLY SOLUBLE DRUGS - Pharmaceutical compositions having improved dissolution profiles for drugs therein is disclosed. | 12-23-2010 |
